Compositions and methods of use for treating copper deficiency
By using iresimilar to imitate the function of copper transporter, the problem of ineffective copper delivery in copper supplementation methods was solved, and the homeostasis recovery of copper in cells and mitochondria and the rescue of respiratory chain function was achieved, showing the symptoms of copper metabolism Potential therapeutic effects.
Patent Information
- Application Number
- CN202411150828.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-07-12
- Filing Date
- 2019-07-12
- Publication Date
- 2024-11-26
AI Technical Summary
Existing copper supplementation methods fail to effectively treat mitochondrial diseases caused by human copper deficiency, which may lead to copper being unable to effectively transport into cells due to ineffective copper delivery mechanisms.
Using ilestemu (ES) as a copper delivery agent, by mimicking the function of missing copper transporters and chaperones, increases copper content in cells and mitochondria, restores copper homeostasis, and transports copper across biofilms to restore mitochondrial respiration Chain function.
At low nanomolar concentrations, iresimole significantly increased copper levels in cells and mitochondria, saving cellular functions in copper-deficient yeast, zebrafish and mammalian models, with the potential to treat copper metabolism disorders.
Smart Images

Figure CN119015309A_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese patent application 201980060081.5, “Compositions and methods of use for treating copper deficiency,” filed on July 12, 2019.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS This patent application claims priority to U.S. Provisional Application No. 62 / 697,207, filed on July 12, 2018, and incorporates its entire disclosure by reference.
[0003] Statement Regarding Federally Sponsored Research This invention was made with government support under GM111672 awarded by the National Institutes of Health. The government has certain rights in this invention. Technical Field
[0004] The present disclosure relates generally to copper deficiency, and more particularly, but not by way of limitation, to compositions and methods of use thereof for treating copper deficiency. Background Art This section provides background information to facilitate a better understanding of various aspects of the present disclosure. It should be understood that the statements in this section of this document should be read in this light, and not as admissions of prior art.
[0006] Copper is an important cofactor for cytochrome c oxidase (CcO), the terminal enzyme of the mitochondrial respiratory chain. Inherited loss-of-function mutations in several genes encoding proteins required for copper delivery to CcO lead to reduced CcO activity and severe pathology in affected infants. Copper supplementation restores CcO function in patient cells with mutations in two of these genes (COA6 and SCO2), suggesting potential treatment options. However, direct copper supplementation has not yet become therapeutically effective in human patients, highlighting the need to identify highly efficient copper transport pharmacological agents. Using a candidate-based approach, an investigational anticancer drug, elesimol (ES), was identified that rescues respiratory defects in COA6-deficient yeast cells by increasing mitochondrial copper content and restoring CcO activity. ES also rescues respiratory defects in other yeast mutants of copper metabolism, suggesting wider applicability. Low nanomolar concentrations of ES restore the copper-containing subunits of CcO in a zebrafish model of copper deficiency and in a range of copper-deficient mammalian cells (including those derived from SCO2 patients). The findings presented herein reveal that ES can restore intracellular copper homeostasis by mimicking the functions of missing copper transporters and chaperones and may have the potential to treat human copper metabolism disorders.
[0007] Genetic pathogenic mutations in genes required for the delivery of copper to cytochrome c oxidase (CcO) disrupt mitochondrial energy metabolism and lead to fatal mitochondrial diseases. Previous attempts to treat human patients with these mutations by direct copper supplementation have been unsuccessful, likely due to ineffective copper delivery to mitochondria. A targeted search was conducted to identify compounds that can effectively transport copper across biological membranes, and an investigational anticancer drug, elesimomod, was identified as the most effective copper delivery agent. Elesemomod rescues CcO function in yeast, zebrafish, and mammalian models of copper deficiency by increasing cellular and mitochondrial copper content. Therefore, the present disclosure provides the possibility of repurposing this anticancer drug for the treatment of copper metabolism disorders.
[0008] Development of this invention was funded in part by the Welch Foundation under Grant No. A-1810. Summary of the invention This Summary is provided to introduce some concepts that are further described below in the Detailed Description. This Summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to be used as an aid in limiting the scope of the claimed subject matter.
[0010] In some embodiments, the disclosure relates to a method for restoring cytochrome c oxidase (CcO) activity in a subject in need thereof. In some embodiments, the method comprises administering a therapeutically effective amount of elesimol and rescuing cell defects in a subject having a defect or mutation in at least one of SOD1, AT-1, AP1S1, COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In some embodiments, the administration increases at least one of cellular copper content and mitochondrial copper content. In some embodiments, the administration reconstructs subcellular copper homeostasis in copper-deficient cells. In some embodiments, the administration improves at least one defect in cellular copper homeostasis and mitochondrial copper homeostasis.
[0011] In some embodiments, the method further comprises mimicking the function of a missing copper transporter or chaperone and restoring intracellular copper homeostasis. In some embodiments, the method further comprises transporting copper across biological membranes and restoring mitochondrial respiratory chain function. In some embodiments, the therapeutically effective amount of elesimo for human subjects is within the range of about 0.589 mg / kg body weight. In some embodiments, the therapeutic dose range of elesimo in humans is 0.243-1.17 mg / kg. In some embodiments, the elesimo is an elesimo analog, a mimetic, or a derivative thereof. In some embodiments, the method further comprises bypassing at least one of SCO2 function and COA6 function.
[0012] In another embodiment, the disclosure relates to a method for treating a copper metabolism disorder. In some embodiments, the method comprises administering a therapeutically effective amount of elesimol to a subject, wherein the disorder is caused by a defect or mutation in a gene, the gene including, but not limited to, SOD1, AT-1, AP1S1, COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or a combination thereof. In some embodiments, the disorder is caused by a mutation in the ATP7A gene. In some embodiments, the disorder may include, but not limited to, occipital horn syndrome, X-linked distal hereditary motor neuropathy, amyotrophic lateral sclerosis, Lou Gehrig's disease, Alzheimer's disease, Huppke-Brendel syndrome, MEDNIK syndrome, or a combination thereof. In some embodiments, the administration increases at least one of cellular copper content and mitochondrial copper content. In some embodiments, the administration reconstructs subcellular copper homeostasis in copper-deficient cells. In some embodiments, the administration improves defects in at least one of cellular copper homeostasis and mitochondrial copper homeostasis.
[0013] In some embodiments, the method further comprises mimicking the function of a missing copper transporter or chaperone and restoring intracellular copper homeostasis. In some embodiments, the method further comprises transporting copper across biological membranes and restoring mitochondrial respiratory chain function. In some embodiments, the method comprises administering elesimo and copper to the subject in combination. In some embodiments, the therapeutically effective amount is within the range of about 0.589 mg / kg body weight. In some embodiments, the therapeutic dose range of elesimo in humans is 0.243-1.17 mg / kg.
[0014] In some embodiments, the elesimol is elesimol complexed with copper (Cu(II)-ES), an elesimol analog, an elesimol mimetic, or a derivative thereof. In some embodiments, the method further comprises bypassing at least one of SCO2 function and COA6 function.
[0015] In another embodiment, the present disclosure relates to having Fig. 11B In some embodiments, X1, X2, X3 and X4 can each independently include, but are not limited to, O, S, Se, Te, Po, N (R7) m 、P(R7) m 、As(R7) m 、Sb(R7) m Or Bi(R7) mor a combination thereof. In some embodiments, m is 0 or 1. In some embodiments, R1, R2, R3, R4, R5 and R6 can each independently include, but are not limited to -H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen, nitro, cyano, guanadino, -OR8, -NR 10 R 11 , _C(O)R8, _C(O)OR8, _OC(O)R8, _C(O)NR 10 R 11 , _NR9C(O)R8, _OP(O)(OR8)2, _SP(O)(OR8)2, _SR8, _S(O) p R8, _OS(O) p R8, _S(O) p OR8, _NR9S(O) p R8, _S(O) p NR 10 R 11 , aromatic groups or combinations thereof. In some embodiments, R7 may include, but is not limited to, -H, -OR8, -NR 10 R 11 , _C(O)R8, _C(O)OR8, _OC(O)R8, _C(O)NR 10 R 11 , _NR9C(O)R8, _OP(O)(OR8)2, _SP(O)(OR8)2, _SR8, _S(O) p R8, _OS(O) p R8, _S(O) p OR8, _NR9S(O) p R8, _S(O) p NR 10 R 11 , alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, halogen, nitro, cyano, guanadino, aromatic group or a combination thereof. In some embodiments, p is 1 or 2. In some embodiments, R8, R9, R 10 and R 11 Each of R and R may independently include, but is not limited to, -H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, halogen, nitro, cyano, guanadino, aromatic groups, or combinations thereof. In some embodiments, R 10 and R 11 At least one of the groups, together with the nitrogen to which they are attached, forms a heterocyclyl or heteroaryl group.
[0016] In another embodiment, the present disclosure relates to a pharmaceutical composition having Fig. 11B In some embodiments, the composition further comprises an excipient, which may include, but is not limited to, a salt, a solvent, a buffer, a diluent, a binder, a compression aid, a granulating agent, a disintegrant, a glidant, a lubricant, a tablet coating, a tablet film, a colorant, or a combination thereof. In some embodiments, X1, X2, X3, and X4 may each independently include, but are not limited to, O, S, Se, Te, Po, N(R7) m 、P(R7) m 、As(R7) m 、Sb(R7) m Or Bi(R7) m or a combination thereof. In some embodiments, m is 0 or 1. In some embodiments, R1, R2, R3, R4, R5 and R6 can each independently include, but are not limited to -H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen, nitro, cyano, guanadino, -OR8, -NR 10 R 11 , _C(O)R8, _C(O)OR8, _OC(O)R8, _C(O)NR 10 R 11 , _NR9C(O)R8, _OP(O)(OR8)2, _SP(O)(OR8)2, _SR8, _S(O) p R8, _OS(O) p R8, _S(O) p OR8, _NR9S(O) p R8, _S(O) p NR 10 R 11 , aromatic groups or combinations thereof. In some embodiments, R7 may include, but is not limited to, -H, -OR8, -NR 10 R 11 , _C(O)R8, _C(O)OR8, _OC(O)R8, _C(O)NR 10 R 11 , _NR9C(O)R8, _OP(O)(OR8)2, _SP(O)(OR8)2, _SR8, _S(O) p R8, _OS(O) p R8, _S(O) p OR8, _NR9S(O) p R8, _S(O) p NR10 R 11 , alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, halogen, nitro, cyano, guanadino, aromatic group or a combination thereof. In some embodiments, p is 1 or 2. In some embodiments, R8, R9, R 10 and R 11 Each of R and R may independently include, but is not limited to, -H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, halogen, nitro, cyano, guanadino, aromatic groups, or combinations thereof. In some embodiments, R 10 and R 11 At least one of the groups, together with the nitrogen to which they are attached, forms a heterocyclyl or heteroaryl group.
[0017] One embodiment of the present invention relates to compounds for use in treating copper metabolism disorders. In some embodiments, the compounds of the present invention are Fig.12 The structure shown in . BRIEF DESCRIPTION OF THE DRAWINGS A more complete understanding of the methods and compositions of the present disclosure may be obtained by referring to the following detailed description in conjunction with the accompanying drawings, in which: Figure 1 The median effective dose (ED) of elesimol is shown 50 ). Yeast coa6Δ cells were cultured in YPGE medium at 37°C in the presence of increasing concentrations (0.01 nM to 1 μM) of elesimol (ES). After 58 hours of growth, cell density was measured by spectrophotometry at 600 nm. Data represent mean ± SD from three independent measurements.
[0019] Figure 2A , 2B , 2C, 2D, and 2E illustrate that elesimol supplementation rescues the CcO assembly defect by restoring mitochondrial copper levels in yeast S. cerevisiae coa6Δ cells. Figure 2A-2C Bioenergetic parameters of wild-type (WT), coa6Δ, and coa6Δ cells supplemented with 20 nM ES grown in YP galactose medium until early stationary growth phase are illustrated. Figure 2A Oxygen consumption rate (OCR) measurements are shown. Figure 2B Quantification of supercomplexes is shown. Figure 2C Quantification of CcO activity is shown. Figure 2D Mitochondrial copper levels are shown. Figure 2ETotal cellular copper content is shown. Error bars represent mean ± SD (n = 3, two-tailed unpaired Student's t-test *p < 0.05, **p < 0.005).
[0020] Figure 3A and 3B The rescue of respiratory growth of coa6Δ cells by elesimol was shown to be dependent on copper availability. BY4741 WT ( Figure 3A ) and coa6Δ( Figure 3B ) cells. Cell density was measured spectrophotometrically at 600 nm at the indicated time points. Data are representative of two independent experiments.
[0021] Figure 4A and 4B Explains that ES supplementation increases Ctrl1 - / - Effects of copper levels (A) and cytochrome c oxidase subunit COX1 and superoxide dismutase SOD1 levels (B) in H9c2 rat cardiomyocytes. ATP5A is a subunit of mitochondrial ATP synthase and was used as a loading control for Western blotting experiments.
[0022] Figure 5A and 5B Cell viability of immortalized and primary human fibroblast cell lines treated with increasing concentrations of elesimol is shown. Figure 5A Immortalized control (MCH46) and SCO2 patient fibroblasts are shown. Figure 5B Shown are primary human skin fibroblasts (MW28) cultured in DMEM glucose-containing medium treated with increasing concentrations of ES for 36 hours. Total cellular ATP levels were quantified by Cell-Titre GLo assay (Promega) to measure cell viability. Data are presented as mean ± SD (n = 3).
[0023] Fig. 6A , 6B , 6C, and 6D illustrate that elesimol treatment improves the morphological defects observed in Coa6 knockdown embryos. Fig. 6A Zebrafish embryos treated with the indicated concentrations of ES are shown. Figure 6B Shown are zebrafish embryos treated with the indicated concentrations of ES, copper, and a combination of the two at 3 hours post fertilization (hpf). Surviving fish were counted at the indicated time points (n > 30 for each treatment). Figure 6CPhenotypic scores of untreated and ES-treated Coa6 knockdown zebrafish embryos at the indicated time points (hpf) are shown. Batches of 50 fertilized embryos injected with translation blocking or mismatch control morpholinos were treated with or without 100 nM ES at 3 hpf and then observed at the indicated time points (n≥30 for each time point and treatment). Fig.6D Shown are heart rates of zebrafish embryos injected with mismatch control morpholinos or Coa6 translation blocking morpholinos and treated with ES at the indicated time points (n≥30 / group; data represent mean±SEM). NT, no treatment; ES, elesimol.
[0024] Figure 7 It was demonstrated that two injections of esimemol-Cu prevented early mortality in Menkes disease (mo-br) mice. Kaplan-Meier survival of mice following subcutaneous injection of ES-Cu(II) on postnatal days 7 and 10. Log-Rank statistical analysis was performed to assess the significance of survival in the mo-br mouse cohort. Mo-br mice were treated with 3.625 mg / kg / dose. ES-Cu(II) experienced a 10-week survival rate of 81.5%, with a mean survival time of 63.4±15.8 days, compared to 14.2±0.2 days for vehicle alone, and an equivalent Cu(II)-2 histidine salt of 1.625 mg / kg / dose. 2+ dose was 18.2±1.1 days, and the equivalent elesimol-only dose of 3.15 mg / kg / dose was 17.0±0.9 days (P<0.0001).
[0025] Figure 8 The average weight gain of mice after subcutaneous injection at postnatal day 7 and 10 is illustrated. Groups and number of mice / groups are named as follows: WT vehicle (n=13), WT Cu(II)-ES (n=12), mo-br vehicle (n=9), mo-brCu(II)-ES (n=27), mo-br Cu(II)-2His (n=6), and mo-br ES (n=6). Growth curves are reported as the mean ± SD of each group measured weekly. The mo-br mice belonging to the vehicle or ES treatment groups did not survive the 2nd week time point (not shown). All mo-br Cu(II)-2His treated mice died before the 3rd week.
[0026] Fig. 9 The inverted wire mesh test of muscle strength in the surviving mice groups evaluated at 5, 10, 15 and 20 weeks is described. The mice were placed on a 43 cm square of 12 mm length with a 1 mm diameter wire. 2Net and inverted 180° for 60 seconds. The best of three trials separated by a 15-minute rest period was recorded every 5 weeks during the mid-light cycle. ANOVA with Dunnett's (two-sided) post hoc test was used to assess significance.
[0027] Fig.10 The motor performance of the surviving mice group at 10 weeks of age evaluated by the accelerating rotating rod is described. The mice were trained for three periods at a constant speed of 4 rpm on the rotating rod (UGO Basile 7650 model) before testing. In order to evaluate motor performance, the mice were placed on the accelerating rotating rod (4 rpm to 40 rpm for 300 seconds, followed by a constant speed of 120 seconds) for a maximum of 420 seconds. The waiting time for falling or passive rotation was recorded, and the average value of each mouse in three trials was taken. All mice were evaluated in a mid-light cycle in a random order. Data were reported as average group mean ± SEM. ANOVA with Dunnett's post hoc test was used to determine significance.
[0028] Fig.11A The chemical structure of elesimol is illustrated.
[0029] Fig. 11B The general chemical structures of analogs of elesimol according to aspects of the present disclosure are illustrated.
[0030] Fig.12 Example analogs of elesimol according to aspects of the present disclosure are described. DETAILED DESCRIPTION It should be understood that in order to realize the different features of each embodiment, the following disclosure provides many different embodiments or examples. The specific examples of components and arrangements are described below to simplify the disclosure. Of course, these are merely examples and are not intended to be limiting. The paragraph titles used in this article are for organizational purposes and should not be construed as limiting the subject matter described.
[0032] Copper is an essential micronutrient required for the assembly and activity of cytochrome c oxidase (CcO), the terminal enzyme of the mitochondrial respiratory chain that catalyzes the reduction of molecular oxygen and drives mitochondrial energy production. CcO is a highly conserved multimeric mitochondrial inner membrane protein complex with two copper-containing subunits, Cox1 and Cox2, which together form its catalytic core. Copper delivery to mitochondria and insertion into these copper-containing subunits is a complex process that requires multiple metallochaperones and accessory proteins. Failure of copper delivery to Cox1 and Cox2 disrupts CcO assembly and leads to hyporespiration.
[0033] Cytosolic copper is delivered to the mitochondrial matrix by the recently identified yeast protein Pic2, where it is stored in a ligand-bound form. The mitochondrial matrix copper pool is the main source of copper ions inserted into the CcO subunit in the mitochondrial intermembrane space (IMS). The mobilization of copper from the mitochondrial matrix to the IMS in order to deliver copper to the copper sites in the CcO subunit requires many evolutionarily conserved proteins. Except for the metal chaperone proteins Cox17, Sco1, Sco2 and Cox11, which have been shown to transfer copper to the CcO subunit in a bucket-brigade manner, the precise molecular functions of these proteins have not yet been resolved. Specifically, Cox17 receives copper from the mitochondrial matrix and transfers it to Cox11 and Sco1 / Sco2, which then metallize the copper sites on Cox1 and Cox2, respectively. Recently, it has also been shown that two other proteins, Coa6 and Cox19, are part of the copper delivery pathway in the IMS.
[0034] In humans, inherited partial loss-of-function mutations in SCO1, SCO2, and COA6 result in CcO deficiency and are associated with liver disease, metabolic acidosis, cardiomyopathy, and neurological defects in affected patients. Copper supplementation rescues CcO deficiency in myoblasts from patients with mutations in SCO2 and restores CcO activity in COA6-deficient yeast and human patient cell lines, suggesting that efficient delivery of copper to mitochondria can restore CcO activity by bypassing SCO2 and COA6 function. To translate these observations in a clinical setting, patients with SCO2 mutations were given subcutaneous injections of copper-histidine. Although copper supplementation improved patients' hypertrophic cardiomyopathy, it did not improve other clinical outcomes or survival. Therefore, human therapies will require more effective mechanisms to restore copper homeostasis. The present disclosure uses yeast coa6Δ cells to identify compounds that can effectively transport copper across biological membranes and restore mitochondrial respiratory chain function over a wide range of concentrations. This approach identified elesimol (ES), which was shown to reconstitute subcellular copper homeostasis in copper-deficient cells, highlighting its therapeutic potential for human copper metabolism diseases.
[0035] ATP7A is an ATP-driven copper transporter that plays an important role in human health. ATP7A is crucially involved in dietary copper uptake from the intestine. In addition, ATP7A delivers copper to many copper-dependent enzymes in the secretory pathway and promotes the transfer of copper to the brain. Inactivating mutations in ATP7A are associated with serious and often fatal pathologies (such as Menkes disease, occipital horn syndrome, and X-linked distal hereditary motor neuropathy). Genetic and biochemical studies have confirmed that pathogenic mutations destroy ATP7A in a variety of ways, including biosynthetic destruction, stability damage, inactivation of copper transport activity, and ATP7A transport. Elisimol is a feasible therapy for treating copper metabolism disorders caused by mutations in ATP7A.
[0036] Working Example Reference will now be made to more specific embodiments of the present disclosure and data providing support for such embodiments. However, it should be noted that the following disclosure is for illustrative purposes only and is not intended to limit the scope of the claimed subject matter in any way.
[0037] Reagents. All copper-binding compounds were purchased from Sigma-Aldrich, except for elesimol (ES), which was purchased from Selleckchem. The yeast-human hybrid (hyCOA6) gene construct was codon-optimized for yeast and used Gene Synthesis (Life Technologies) was used for synthesis. The hybrid gene hyCOA6 was cloned into the pRS416 plasmid under the control of the yeast Coa6 native promoter. The COA6 patient mutation was introduced by site-directed mutagenesis (Agilent Technologies QuikChange Lightning) using hyCOA6 as a template. All primers used in this disclosure are listed in Table 1 as shown below. All constructs were sequenced for verification. Table 1
[0038] Yeast strains and culture conditions. The Saccharomyces cerevisiae strains used in the present disclosure are listed in Table 2 as shown below. Yeast strain authenticity was confirmed by PCR and by replica plating on dropout plates. Yeast cells were cultured in standard YP growth medium or synthetic medium (SC glucose) including YPD (1% yeast extract, 2% peptone and 2% glucose), YPGal (2% galactose), YPGE (3% glycerol + 1% ethanol). For qualitative growth measurements, 10-fold serial dilutions of overnight cultures were blotted on YPD or YPGE plates and incubated at 30°C and 37°C for designated stages. Growth in liquid culture was measured at 600nm by spectrophotometry. Table 2
[0039] Mammalian cell culture. Human control MCH46 and SCO2 patient fibroblasts and rat H9c2 control and Ctr1- / - Cardiomyocytes. Mouse embryonic fibroblasts were cultured in DMEM 10% FBS, 1 mM sodium pyruvate, 1x Minimum Essential Medium Non-Essential Amino Acids (MEM NEAA; Life Technologies 11140), 50 μg / mL uridine, and 1x Pen Strep Glutamine (Life Technologies 10378). All cell lines were cultured at 37°C under 5% CO2 and treated with the indicated concentrations of ES for 3-6 days before harvesting. Whole cell protein was extracted in lysis buffer (BP-115, Boston BioProducts) supplemented with a protease inhibitor cocktail (Roche Diagnostics), and protein concentration was determined by BCA assay (Thermo Scientific).
[0040] Construction of Ctr1 knockout rat H9c2 cell line. CRISPR / Cas9-mediated Ctr1 knockout rat H9c2 cell line was generated by using lentiCRISPR v2 plasmid (Addgene, #52961). The guide RNA (gRNA) sequence targeting exon 1 of the Ctr1 gene was identified using an online CRISPR design tool. The forward (5'CACCGTGGTGATGTTGTCGTCCGTG 3') (SEQ ID NO: 7) and reverse (5'AAACCACGGACGACAACATCACCAC3') (SEQ ID NO: 8) oligonucleotides were inserted into the lentiCRISPR v2 plasmid. PolyJet (SignaGen Laboratories) was used for transfection. Two days after transfection, cells were plated in a 5 The cells were plated on 96-well plates containing 1 μg / mL puromycin selection medium. Each colony formed from a single cell was isolated and established in medium without puromycin. The disruption of the Ctr1 gene was confirmed by genomic DNA sequencing.
[0041] Oxygen consumption measurements. To measure respiration rate, cells were grown to late log phase in YPGal medium and then washed, counted, and expressed as 10 8 Cells / ml were resuspended in fresh YPGal medium. Oxygen consumption rate was then measured at 30° C. using an Oxytherm (Hansatech, Norfolk, UK). Cyanide-sensitive respiration was calculated after addition of 1 mM KCN, and cyanide-insensitive respiration was subtracted from total respiration.
[0042] Immunoblotting and in-gel activity. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Blue Native PAGE (BN-PAGE) were performed to separate denatured and native protein complexes, respectively. For SDS-PAGE, mitochondrial lysates (20 μg) were separated on NuPAGE 4-12% Bis-Tris gels (Life Technologies, Carlsbad, CA). For BN-PAGE, yeast mitochondria were solubilized in a buffer containing 1% digitonin (Life Technologies) by incubation at 4°C for 15 minutes. After spinning at 20,000×g (30 min, 4°C), the clear supernatant was collected, 50× G-250 sample additive was added, and 20 μg of protein was loaded on a 3-12% Native PAGE Bis-Tris gel (Life Technologies). After wet transfer, the membrane was probed with the following primary antibodies: for yeast proteins - Cox2, 1:50,000 (110271; Abcam) and porin, 1:50,000 (110326; Abcam), for mammalian proteins - COX1 (14705; Abcam), COX2 (110258; Abcam), CTR1, COX4 (A21348; Thermo Fisher Scientific), CCS (FL-274; Santa Cruz Biotechnology), GAPDH (G9545, Sigma), ATP5A (14748; Abcam), and β-actin (A2228; Sigma). Western blots were developed using Western Lightning Plus-ECL (PerkinElmer, Waltham, MA). In-gel activity assays for mitochondrial respiratory chain complex IV were performed.
[0043] Cellular and mitochondrial copper measurements. Cellular and mitochondrial copper levels were measured using a Perkin Elmer DRC II inductively coupled plasma-mass spectrometer (ICP-MS). The intact yeast cells and isolated mitochondrial pellets were washed with water containing 100 μM EDTA, weighed, and digested with 40% nitric acid (TraceSELECT, Sigma) at 90°C for 18 h. The samples were diluted in ultrapure metal-free water (TraceSELECT, Sigma) and analyzed by ICP-MS. Copper standard solutions were prepared by appropriately diluting commercially available mixed metal standards (BDH Aristar Plus). Copper concentrations in mammalian cells were also measured by ICP-MS.
[0044] Zebrafish experiments. Zebrafish studies were approved by the Marine Biological Laboratory Institutional Animal Care and Use Committee (#16-38). Wild-type AB strains and Ctr1 heterozygous zebrafish were maintained and crossed using standard methods. Embryos were staged and cultured at 28.5°C in Egg Water. For drug treatment, embryos from Ctr1 heterozygous crosses were incubated in 10nM ES diluted in Egg Water starting at 3 hours post fertilization (hpf). In order to image live embryos at 48hpf, representative embryos of each sample were anesthetized in Tricaine and imaged on an Olympus SZX12 stereomicroscope. For immunoblotting, zebrafish mitochondrial proteins were prepared from 10 days post fertilization (dpf) larvae. Mitochondrial lysates were separated by SDS-PAGE on 4-15% Mini-PROTEAN TGX Gels (Bio-Rad) and then subjected to Western blot analysis using anti-Cox1 (anti-MTCO1; Abcam; ab14705) at 1:5000 and anti-Atp5a (Abcam; ab110273) at 1:5000. Experiments based on morpholino reagents were performed.
[0045] A targeted search for copper binders identified elesimol as the most potent pharmacological agent that rescues the respiratory defect of yeast coa6Δ cells. A number of copper-binding pharmacological agents were tested for their ability to rescue the respiratory defective growth of coa6Δ cells. ES was unique among all compounds tested in that it rescued respiratory growth at low nanomolar concentrations without showing overt toxicity over a wide range of concentrations. ES was found to be highly potent in rescuing the respiratory defect of coa6Δ cells with an ED of 0.8 nM. 50 Rescue of respiratory growth in coa6Δ cells ( Figure 1 ES-mediated growth rescue of coa6Δ cells was also observed on solid growth medium containing nonfermentable carbon. Consistent with the rescue of respiratory growth, ES supplementation restored the oxygen consumption rate of coa6Δ cells to that of wild-type cells ( Figure 2A To determine the biochemical basis for the observed respiratory rescue in coa6Δ cells, the assembly and activity of CcO-containing mitochondrial respiratory chain supercomplexes were measured by native-polyacrylamide gel electrophoresis blotting and in-gel activity assays, respectively. ES supplementation restored the abundance and activity of CcO-containing supercomplexes to near wild-type levels ( Figure 2B-2C). Next, the efficacy of ES in rescuing COA6 mutations observed in human patients was tested by heterologously expressing yeast-human chimeric proteins with patient mutations (W26C, W33R, and E54X) in yeast coa6Δ cells. Similar to coa6Δ cells, 10 nM ES or 10 μM copper supplementation rescued yeast coa6Δ cells expressing patient mutations. These results show that ES is at least 1000 times more potent than copper in rescuing the respiratory growth defect of yeast coa6Δ cells.
[0046] ES scavenges copper from the culture medium, enters the cell as an ES-copper complex, and selectively accumulates in the mitochondria, where it dissociates from copper. Consistent with this concept, a near-complete rescue of mitochondrial copper levels was observed in coa6Δ cells supplemented with ES ( Figure 2D ES supplementation also modestly increased total cellular copper levels ( Figure 2E To further confirm that ES increases mitochondrial copper levels by actively transporting extracellular copper into cells, copper availability in the extracellular compartment was reduced by co-treatment of ES with the known copper chelator bathocuproine disulfonate (BCS). As expected, BCS treatment resulted in reduced respiratory growth in wild-type cells, which was rescued by co-treatment with ES, suggesting that ES is also able to overcome pharmacological copper deficiency by outcompeting BCS ( Figure 3A In addition, ES-mediated rescue of coa6Δ was reduced in the presence of BCS ( Figure 3B ). To determine whether ES could bypass the mitochondrial copper transporter Pic2, ES supplementation was performed in pic2Δ and coa6Δpic2Δ cells. Although no respiratory growth defect was observed in pic2Δ cells under the conditions tested, ES did rescue coa6Δpic2Δ cells, suggesting that the compound can deliver copper to mitochondria independently of Pic2 function. These results suggest that ES-mediated rescue of CcO function is driven by its ability to transport extracellular copper to mitochondria in coa6Δ cells.
[0047] ES rescues many different yeast mutants with impaired copper metabolism. To test the specificity of ES-mediated rescue, a number of yeast mutants of genes required for maintaining cellular and mitochondrial copper homeostasis were selected. Genes were prioritized based on their evolutionary conservation, the presence of pathogenic mutations in humans, and / or the presence of relevant mouse phenotypes (Table 3, shown below). These yeast mutants displayed a significant respiratory defective growth phenotype after two days of growth at 37°C in non-fermented medium, which became less obvious after four days of growth. Although to varying degrees, most yeast mutants were rescued by ES supplementation, reflecting their unique roles in cellular and mitochondrial copper homeostasis. The inability of ES to rescue sco1Δ cells may be due to the specific role of Sco1 as a metallochaperone in inserting copper into the Cox2 subunit of CcO. It was noted that higher concentrations of ES were required to rescue ctr1Δ cells, which is consistent with the severe reduction in copper levels in cells lacking Ctr1. Overall, these results suggest the broad applicability of ES in improving defects in cellular and mitochondrial copper homeostasis. Table 3
[0048] ES supplementation rescues CcO subunit levels in mammalian cell lines with genetic defects in copper metabolism. To extend the findings in yeast and test the efficacy of ES in a mammalian cell culture model of copper deficiency, a Ctr1 knockout rat H9c2 cardiomyocyte cell line was constructed. - / - As expected, loss of Ctr1 resulted in a ~4-fold decrease in intracellular copper levels ( Figure 4A ) and a concomitant decrease in the levels of the CcO subunit COX1 and superoxide dismutase SOD1 ( Figure 4B ). The verified Ctr1 - / - Cell lines were used to test the efficacy of ES in rescuing COX1 (the copper-containing subunit of CcO) and SOD1 (superoxide dismutase, another copper-containing enzyme SOD1). Figure 4A As shown in - / - Cells showed reduced copper levels, which were restored by supplementation with 5 nM ES. Figure 4B Display, Ctr1 - / - Treatment of cells with 5 nM ES also restored the levels of COX1 and SOD1. - / -A dose-dependent rescue of COX1 levels was observed in mouse embryonic fibroblasts (MEFs). However, ES toxicity was noted at higher doses, which was reflected in reduced COX1 levels in control MEFs. Finally, the efficacy of ES in rescuing CcO deficiency in SCO2 patient fibroblasts, which had previously been shown to have COX2 deficiency, was tested. Unlike copper supplementation, ES treatment was able to partially rescue the steady-state levels of COX2 in a dose- and time-dependent manner. Notably, ES toxicity occurred at concentrations 20-fold higher than the dose that rescued COX2 levels ( Figure 5A Consistent with the known anticancer activity of ES cells, when compared to primary cultures of the same cell type ( Figure 5B ) compared to the immortalized cell line ( Figure 5A ) In summary, these results suggest that low nanomolar concentrations of ES are effective in rescuing mitochondrial copper deficiency and restoring CcO levels in mammalian cell lines with genetic defects in copper homeostasis.
[0049] ES supplementation rescues copper deficiency phenotypes in zebrafish models. To determine whether ES can rescue phenotypes associated with copper deficiency in an intact developing vertebrate model, zebrafish embryos with a null mutation in the gene encoding the plasma membrane copper import protein Ctr1 were used. Zebrafish were chosen because of the ability to rapidly monitor pigmentation defects resulting from the copper requirement for tyrosinase, an enzyme that catalyzes a key step in melanin biosynthesis. Wild-type zebrafish embryos have a characteristic melanin pigmentation pattern visible at 48 hpf. To determine whether ES can rescue copper deficiency phenotypes in zebrafish, zebrafish embryos from heterozygous Ctr1 crosses were incubated in 10 nM ES and compared to untreated embryos. It was found that, as expected, approximately 25% of untreated embryos from Ctr1 heterozygous crosses lacked melanin deposition, whereas all ES-treated embryos from the same cross were pigmented. Similarly, rescue of pigmentation defects was observed at 100 nM ES, but copper at an equivalent dose failed to rescue the defect. Ctr1 - / - The mutants may also exhibit CcO assembly defects due to mitochondrial copper deficiency. To determine whether ES can rescue the observed CcO assembly defects, embryonic clutches were grown from heterozygous Ctr1 crosses in the presence of ES until 10 dpf, and Cox1 levels in their mitochondrial extracts were measured. - / - The mutant exhibited a severe reduction in Cox1 levels, which was almost completely rescued by treatment with ES.
[0050] To further establish the potential of ES for the treatment of metabolic diseases involving defective copper delivery to mitochondria, the efficacy of ES in rescuing phenotypes associated with Coa6 knockdown in zebrafish embryos was tested. First, the maximum tolerated dose of ES for zebrafish embryos was determined to be 100 nM ( Fig. 6A Consistent with the mechanism of action of ES, it was observed that co-supplementation of 100 nM ES with 100 nM copper resulted in 100% lethality ( Figure 6B ). Zebrafish embryos injected with the Zfcoa6 translation-blocking morpholino exhibited significant morphological defects characterized by pericardial edema, smaller heads and eyes, and bent tails. The severity of these phenotypes was scored at four different time points, 24, 48, 72, and 96 hpf (shown in Table 4 below), and rescue with 100 nM ES treatment was observed as early as 48 hpf ( Figure 6C ). Given that one of the most striking features of Coa6 deficiency in this model is the marked cardiac edema and decreased heart rate, we next determined whether ES treatment could rescue these phenotypes. Indeed, 100 nM ES treatment prevented pericardial edema and significantly increased the heart rate of Coa6 knockdown zebrafish embryos at 72 and 96 hpf, while not altering the heart rate of control embryos ( Fig.6D ). These results demonstrate the efficacy of ES in rescuing phenotypes associated with copper deficiency in intact living vertebrates. Table 4
[0051] Mitochondrial disorders of copper metabolism represent a subset of inborn errors of mitochondrial energy metabolism for which there is currently no therapy. Previous attempts to use direct copper supplementation as a treatment regimen have been unsuccessful, probably due to the strict regulation of systemic copper levels. Therefore, there is an unmet need for the development of better copper delivery agents. With this goal in mind, many clinically used pharmacological agents have been tested on a yeast mitochondrial disease model of COA6 deficiency, and ES has been identified as the most effective and best tolerated compound capable of restoring mitochondrial function. Subsequent experiments on other yeast, mouse, human and zebrafish models have established the wide applicability of ES in the treatment of mitochondrial, cellular and organismal copper deficiency. ES has undergone multiple human clinical trials, in which it has shown a favorable toxicity profile. Therefore, the discovery presented herein provides the possibility of reusing the anticancer drug to treat copper metabolism disorders.
[0052] Pharmacological interventions that alter the subcellular concentration and distribution of metals in a targeted manner may have therapeutic benefits. For example, co-administration of copper with disulfiram (a drug approved by the Food and Drug Administration) increases CcO activity in the brain of a mouse model of Menkes disease (a genetic disorder characterized by systemic copper deficiency). Similarly, Cu has been shown toII -ATSM is effective in a transgenic mouse model of amyotrophic lateral sclerosis. However, comparative studies of the efficacy of these clinically used copper complexes in copper deficiency models are lacking. Therefore, the present disclosure identifying ES as the most effective pharmacological agent among many clinically used copper chelators and ionophores represents an important advance. The physicochemical properties of ES, including its binding affinity, its specificity for copper, and the redox potential of the ES-copper complex, allow it to mimic the copper metallochaperone protein. ES has a higher affinity for copper (II) than copper (I), which allows it to remove copper from the extracellular environment where copper is more likely to exist in an oxidized state. ES is less likely to deprive intracellular proteins of copper due to the higher prevalence of copper in a reduced state in the intracellular environment.
[0053] Although there is selective enrichment of ES-copper complexes in mitochondria, the rescue of yeast atx1Δ and ccc2Δ, which have impaired copper homeostasis in the Golgi compartment, suggests that ES is also able to deliver copper to other subcellular compartments. - / - The rescue of pigmentation defects caused by secretory pathway enzyme defects observed in zebrafish also indicates that ES can increase copper levels in other organelles. Finally, the rescue of respiratory growth defects in ccs1Δ cells (which lack the metal chaperone of the cytosolic protein Sod1) suggests that ES can also increase cytosolic copper levels. Although the mechanism by which ES can deliver copper to different subcellular compartments is not fully understood, some ES-copper complexes may dissociate before reaching the mitochondria, thereby releasing free copper in the cytoplasm. Alternatively, excess mitochondrial copper may "leak" from the mitochondria and make it available to other organelles. Despite this mechanism, this interesting observation suggests that ES can effectively treat more common copper deficiency disorders, including Menkes disease, as discussed further below.
[0054] Mouse Model of Human Copper Deficiency In vivo mouse model data demonstrating the efficacy of Cu-elesimol complex [Cu(II)-ES]. To evaluate the potential of Cu(II)-ES in a mouse model of human copper deficiency disorders, a well-characterized mottled (mo-br) mouse model (C57BL / 6-Atp7a) that closely mimics the clinical and biochemical phenotype of Menkes disease was selected. mo-br / J, Jackson Laboratory Stock #002566). Like in humans, these mice are characterized by mutations in ATP7a, which is an X-linked gene and therefore its mutations only affect males. Importantly, as with human Menkes disease patients, mo-br mice cannot be rescued by injection of Cu salts. Mice affected by Menkes disease typically die by approximately day 14, and on day 10 after birth, they begin to show neurological deficits, e.g., seizures, loss of forward reflex, etc. Two subcutaneous doses of Cu(II)-ES at 3.625 mg / kg / dose administered on days 7 and 10 after birth were sufficient to rescue mo-br mice from death ( Figure 7 Notably, vehicle-, copper-histidine-, or elesimol-alone-treated mo-br mice died within 20 days of life, whereas 81.5% of Cu(II)-ES-treated mo-br mice survived until day 70 ( Figure 7 All wild-types treated with vehicle or Cu(II)-ES survived until day 70 without adverse effects, suggesting that the current dosing and treatment regimen was nontoxic to mice.
[0055] To test whether Cu(II)-ES treatment of mo-br mice improved only survival or also growth, body weight gain was monitored after two injections of Cu(II)-ES. Mo-br mice treated with Cu(II)-ES showed a similar pattern of weight gain as wild-type mice, however, weight gain was slightly lower (P<0.001) at all time points evaluated, as shown in Figure 8 Mild growth defects were noted in wild-type mice treated with Cu(II)-ES compared with vehicle-treated wild-type mice at weeks 2, 3, and 4 of evaluation (P = 0.0004, 0.0003, and 0.026), but these mice recovered by week 5 (P > 0.05, weeks 5-10), as shown in Figure 8 These data show that Cu(II)-ES treated mo-br mice not only survived but also thrived, and Cu(II)-ES treatment did not have any long-term growth retardation effect on wild-type mice.
[0056] In addition to survival and growth measurements, a number of neurological tests were performed to evaluate the efficacy of ES-mediated copper delivery to the brain and the overall health of the animals. As previously described, these tests were performed on mice treated only twice (days 7 and 10), and are described in more detail below.
[0057] Wire suspension test. This test evaluates the motor function and muscle strength of animals. Wild-type mice treated with vehicle or Cu(II)-ES did not differ in their hanging time, suggesting that the administration of Cu(II)-ES did not cause any muscle or motor function toxicity ( Fig. 9 In terms of drug efficacy, Cu(II)-ES-treated mo-br mice exhibited hanging time statistically similar to that of vehicle-treated wild-type mice until week 15, but muscle strength was significantly reduced at week 20 (*P=0.01)( Fig. 9 This decline in muscle function in mo-br mice after week 15 suggests that copper levels may be declining after week 15 of life.
[0058] Rotarod test. This test evaluates neuromotor function, including balance, endurance, grip strength, and motor coordination. It involves placing adult mice on a horizontally oriented rotating rod suspended above the cage floor and monitoring the time until they fall. Fig.10 As shown in, mo-br mice rescued by Cu(II)-ES treatment showed significantly reduced latency to fall compared to vehicle-treated wild-type mice, with an average fall time of 222.0±34.5 seconds, compared to 379.0±51.5 seconds (***P<0.0001). Wild-type mice treated with Cu(II)-ES showed no significant difference compared to vehicle-treated wild-type mice, with an average fall time of 326.3±37.8 seconds (P=0.182). This data suggests that the current dose and treatment regimen of ES-Cu (2 injections of 14.5 μg ES-Cu each on postnatal days 7 and 10) partially rescues neuromotor function.
[0059] Results and Discussion of the Mouse Model of Human Copper Deficiency In vivo mouse model data suggest that Cu(II)-ES preparations are effective in many human disorders characterized by dysregulation of copper metabolism. For example, Cu(II)-ES preparations are effective for occipital horn syndrome and X-linked distal hereditary motor neuropathy (both of which are caused by mutations in the ATPA7A gene and are "milder" versions of Menkes disease). In addition, Cu(II)-ES preparations may be effective for amyotrophic lateral sclerosis or Lou Gehrig's disease. Amyotrophic lateral sclerosis is caused by mutations in Cu / Zn-superoxide dismutase (SOD1), and increasing the delivery of copper to SOD1 is therapeutically beneficial.
[0060] In addition, Cu (II) -ES preparations may be effective for Alzheimer's disease. The notable feature of Alzheimer's disease is the accumulation of extracellular β-amyloid protein (Aβ) plaques in the brain. It has been shown that copper delivery by diet or pharmacological means can reduce interstitial Aβ and improve cognitive function in transgenic mouse models of Alzheimer's disease. And, Cu (II) -ES preparations may be effective for Huppke-Brendel syndrome. The syndrome is caused by mutations in the AT-1 gene encoding the endoplasmic reticulum membrane acetyl-CoA transporter, which is required for the acetylation of one or more copper proteins. Mutations in AT-1 lead to lower serum copper levels and severe neurological defects, so Cu (II) -ES may be therapeutically beneficial in this case. In addition, Cu (II) -ES preparations may be effective for MEDNIK syndrome. The syndrome is caused by mutations in the AP1S1 gene and is characterized by copper metabolism disorders, wherein the expression of cytochrome c oxidase and copper-dependent enzyme SOD1 is reduced.
[0061] Therefore, it is anticipated that Cu(II)-ES preparations may be effective in a number of human disorders characterized by dysregulation of copper metabolism, including, but not limited to, occipital horn syndrome, X-linked distal hereditary motor neuropathy, amyotrophic lateral sclerosis, Lou Gehrig's disease, Alzheimer's disease, Huppke-Brendel syndrome, MEDNIK syndrome, or combinations thereof and similar disorders.
[0062] It has been demonstrated above that two injections of Cu(II)-elesimol administered by subcutaneous route at 3.635 mg / kg each on days 7 and 10 after birth are effective. This dose was selected based on the expected systemic copper content of mice. It is expected that a 4-gram pup at 7 days of age has about 4 μg of systemic copper. Therefore, two doses of 3.635 mg / kg Cu(II)-elesimol were selected, each containing 2 μg equivalents of copper for a total dose of 4 μg. Based on these experiments, a dose range of 3-14.5 mg / kg total Cu(II)-elesimol administered within the first 10 days of life may be effective in improving Menkes disease-related phenotypes in mo-br mice.
[0063] In view of the foregoing, in some embodiments, the present disclosure further relates to therapeutically effective doses in human subjects with disorders characterized by dysregulation of copper metabolism. Thus, human doses can be extrapolated based on the above data and are readily apparent to those skilled in the art.
[0064] For example, in some embodiments, the therapeutic dose of elesimol-Cu(II) in humans is approximately about 0.589 mg / kg body weight. Thus, for a human child weighing 4 kg, the dose is approximately 2.36 mg. In some embodiments, the therapeutic dose range of elesimol in humans is 0.243-1.17 mg / kg. Human doses are calculated according to Nair and Jacob (2016) Journal of Basic and Clinical Chemistry, Vol. 7(2):27-31.
[0065] Although the most effective elesimol formulations have been shown to be dissolved in Cu(II)-elesimol in solution, but other embodiments are readily envisioned. For example, in some embodiments, elesimol analogs, mimetics, and derivatives thereof can be used as substitutes for elesimol. Fig.11A The chemical structure of elesimol is illustrated.
[0066] In some embodiments, an elesimol analog, mimetic, or derivative may have Fig. 11B Chemical structures depicted in . Fig. 11B In some embodiments, X1, X2, X3 and X4 may each independently include O, S, Se, Te, Po, N(R7) m 、P(R7) m 、As(R7) m 、Sb(R7) m Or Bi(R7) m In some embodiments, m may include, but is not limited to, 0 or 1.
[0067] Still reference Fig. 11B In some embodiments, R1, R2, R3, R4, R5 and R6 can each independently include -H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen, nitro, cyano, guanadino, -OR8, -NR 10 R 11 , -C(O)R8, -C(O)OR8, -OC(O)R8, -C(O)NR 10 R 11 , -NR9C(O)R8, -OP(O)(OR8)2, -SP(O)(OR8)2, -SR8, -S(O) p R8, -OS(O) p R8, -S(O) p OR8, -NR9S(O) p R8, -S(O) p NR10 R 11 , aromatic groups or combinations thereof.
[0068] Still reference Fig. 11B In some embodiments, R7 can each independently include -H, -OR8, -NR 10 R 11 , -C(O)R8, -C(O)OR8, -OC(O)R8, -C(O)NR 10 R 11 , -NR9C(O)R8, -OP(O)(OR8)2, -SP(O)(OR8)2, -SR8, -S(O) p R8, -OS(O) p R8, -S(O) p OR8, -NR9S(O) p R8, -S(O) p NR 10 R 11 , alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, halogen, nitro, cyano, guanadino, aromatic group or their combination. In some embodiments, p can include, but is not limited to 1 or 2.
[0069] Still reference Fig. 11B In some embodiments, R8, R9, R 10 and R 11 Each of R and R may independently include -H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, halogen, nitro, cyano, guanadino, aromatic groups, or combinations thereof. 10 and R 11 Each independently may be taken together with the nitrogen to which they are attached to form a heterocyclyl or heteroaryl group.
[0070] In some embodiments, the compounds described above may be Fig. 11B The pharmaceutical composition of the chemical structure depicted in, or its tautomer, pharmaceutically acceptable salt, solvate, clathrate or prodrug. In some embodiments, the compound may also include salts, solvents, buffers, diluents, binders, compression aids, granulators, disintegrants, glidants, lubricants, tablet coatings or films, colorants or combinations thereof.
[0071] Other examples of chemical structures of elesimol analogs, mimetics, and derivatives contemplated in the present disclosure are Fig.12 Depicted in.
[0072] In view of the foregoing, in some embodiments, the present disclosure relates to a method for restoring cytochrome c oxidase (CcO) activity in a cell. In some embodiments, the method comprises contacting the cell with a therapeutically effective amount of elesimomod. In some embodiments, the contact increases cellular and mitochondrial copper content. In some embodiments, the contact reconstructs subcellular copper homeostasis in copper-deficient cells. In some embodiments, the contact rescues respiratory defects in cells defective in COA6, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In some embodiments, the contact improves defects in cellular and mitochondrial copper homeostasis. In some embodiments, the therapeutically effective amount of elesimomod can restore intracellular copper homeostasis by mimicking the function of a missing copper transporter or chaperone. In some embodiments, the therapeutically effective amount of elesimomod effectively transports copper across biological membranes and restores mitochondrial respiratory chain function.
[0073] In additional embodiments, the disclosure relates to methods of treating cellular or mitochondrial copper deficiency in a subject in need thereof. In some embodiments, the methods include administering a therapeutically effective amount of elesimol. In other embodiments, the disclosure relates to a method of rescuing CcO deficiency in fibroblasts from a subject with a SCO2 mutation and restoring CcO activity in COA6-deficient yeast, wherein the method includes administering a therapeutically effective amount of elesimol, wherein the elesimol allows efficient delivery of copper to mitochondria to restore CcO activity by bypassing SCO2 and COA6 function.
[0074] In other embodiments, the disclosure relates to a method of treating a human disorder of copper metabolism. In some embodiments, the method comprises administering a therapeutically effective amount of elesimol, alone or in the presence of copper. In some embodiments, the disorder is caused by a mutation in the ATP7A gene. In some embodiments, the disorder is Menkes disease, occipital horn syndrome, or X-linked distal hereditary motor neuropathy.
[0075] Although various embodiments of the present disclosure have been illustrated in the drawings and described in the foregoing detailed description, it should be understood that the disclosure is not limited to the embodiments disclosed herein, but is capable of many rearrangements, modifications and substitutions without departing from the spirit of the disclosure set forth herein.
[0076] As understood by those of ordinary skill in the art, the term "substantially" is defined as to a large extent but not necessarily entirely as specified. In any disclosed embodiment, the terms "substantially", "approximately", "generally" and "about" may be replaced by the specified "within [percentage] of...", where percentages include 0.1%, 1%, 5% and 10%.
[0077] The foregoing summarizes the features of several embodiments so that those skilled in the art can better understand the aspects of the present disclosure. Those skilled in the art will appreciate that they can easily use the present disclosure as a basis for designing or modifying other methods and compositions, which are used to achieve the same purpose and / or achieve the same advantages of the embodiments introduced herein. Those skilled in the art will also appreciate that such equivalent constructions do not depart from the spirit and scope of the present disclosure, and that they can make different changes, substitutions and changes herein without departing from the spirit and scope of the present disclosure. The scope of the present invention should only be determined by the wording of the appended claims. The term "comprising" in the claims means "at least including", so that the list of elements listed in the claims is an open group. Unless explicitly excluded, the terms "one / kind (a)", "one / kind (a)" and other singular terms are intended to include their plural forms.
Claims
1. A composition for treating a copper metabolism disorder, wherein the composition comprises a therapeutically effective amount of elesimol, and wherein the disorder is caused by a defect or mutation in a gene selected from SOD1, AT-1, AP1S1, COA6, SCO1, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or a combination thereof.
2. A composition for use according to claim 1, wherein the composition comprises copper.
3. The composition for use according to claim 1, wherein the disorder is caused by a mutation in the ATP7A gene.
4. The composition for use according to claim 1, wherein the condition is selected from occipital horn syndrome, X-linked distal hereditary motor neuropathy, amyotrophic lateral sclerosis, Lou Gehrig's disease, Alzheimer's disease, Huppke-Brendel syndrome, MEDNIK syndrome, Menkes disease, Wilson disease or a combination thereof.
5. The composition for use according to claim 1, wherein the elesimol is an elesimol analog, mimetic or a derivative thereof.
6. The composition for use according to claim 1, wherein the composition can be administered by injection.
7. A composition for use according to claim 2, wherein elesimol is complexed with copper.
8. The composition for use according to claim 2, wherein the composition can be administered by injection.
9. Use of a composition for treating a copper metabolism disorder, wherein the composition comprises a therapeutically effective amount of elesimol, and wherein the disorder is caused by a defect or mutation in a gene selected from SOD1, AT-1, AP1S1, COA6, SCO1, SCO2, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or a combination thereof.
10. The use according to claim 9, wherein the composition comprises copper.
11. The use according to claim 9, wherein the disease is caused by a mutation in the ATP7A gene.
12. The use according to claim 9, wherein the disorder is selected from occipital horn syndrome, X-linked distal hereditary motor neuropathy, amyotrophic lateral sclerosis, Lou Gehrig's disease, Alzheimer's disease, Huppke-Brendel syndrome, MEDNIK syndrome, Menkes disease, Wilson disease, or a combination thereof.
13. The use according to claim 9, wherein the elesimol is an elesimol analog, mimetic or derivative thereof.
14. The use according to claim 9, wherein the composition can be administered by injection.
15. The use according to claim 10, wherein the elesimol is complexed with copper.
16. The use according to claim 10, wherein the composition is administrable by injection.
